PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsTenecteplase
Tnkase, Metalyse(tenecteplase)
Metalyse, TNKase (tenecteplase) is an enzyme pharmaceutical. Tenecteplase was first approved as Tnkase on 2000-06-02. It is used to treat coronary thrombosis and myocardial infarction in the USA. It has been approved in Europe to treat myocardial infarction.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Tnkase
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Tenecteplase
Tradename
Proper name
Company
Number
Date
Products
TNKasetenecteplaseGenentechN-103909 RX2000-06-02
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
tnkaseBiologic Licensing Application2024-12-18
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AD: Enzymes, antithrombotic
B01AD11: Tenecteplase
HCPCS
Code
Description
J3101
["Injection, tenecteplase, 1 mg"]
Clinical
Clinical Trials
118 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Ischemic strokeD0000832421192861261
StrokeD020521EFO_0000712I63.91172461358
IschemiaD007511EFO_000055618134530
InfarctionD007238EFO_0009463387724
Myocardial infarctionD009203EFO_0000612I21287622
Cerebral infarctionD002544I631552416
St elevation myocardial infarctionD00007265723318
Pulmonary embolismD011655EFO_0003827I2612115
EmbolismD00461712115
ThrombosisD013927415
Show 4 more
Indications Phases 3
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Respiratory insufficiencyD012131J96.911
Ventricular dysfunctionD01875411
Cerebral arterial diseasesD002539EFO_100085911
Brain ischemiaD002545EFO_0003883I67.8211
Indications Phases 1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NecrosisD00933611
Brain stem infarctionsD020526EFO_1000847G46.311
Thrombotic strokeD00008324411
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTenecteplase
INNtenecteplase
Description
Tenecteplase, sold under the trade names TNKase, Metalyse and Elaxim, is an enzyme used as a thrombolytic drug.
Classification
Enzyme
Drug classenzymes: tissue-type plasminogen activators
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID
RxCUI
ChEMBL IDCHEMBL2108791
ChEBI ID
PubChem CID
DrugBankDB00031
UNII IDWGD229O42W (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 2,600 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
1,886 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use